Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC-0111 in Advanced Solid Tumours
NCT02215850Phase 1Completed
- Sponsor
- Welichem Biotech
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SLC-0111 in solid tumor, sponsored by Welichem Biotech. Primary endpoint: Number of participants with adverse events at 1 year. Started Oct 2014; status: completed.
02
Drugs
SLC-0111
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02215850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215850.